文章摘要
蔡俊霞,吴锦昌,王 彬,谭 洁.DC-CIK联合化疗治疗晚期胃癌的近期疗效观察[J].南京医科大学学报,2014,(1):036~040
DC-CIK联合化疗治疗晚期胃癌的近期疗效观察
Short-term curative efficacy of DC-CIK cell-therapy combined with chemotherapy on patients with advanced gastric cancer
投稿时间:2013-06-29  
DOI:10.7655/NYDXBNS20140108
中文关键词: 树突状细胞  细胞因子诱导的杀伤细胞  胃癌  过继免疫治疗
英文关键词: dendritic cells  cytokine induced killer cells  gastric cancer  adoptive immunotherapy
基金项目:苏州市科技发展计划项目(SZS201004)
作者单位
蔡俊霞 南京医科大学附属苏州市立医院肿瘤科,江苏 苏州 215001 
吴锦昌 南京医科大学附属苏州市立医院肿瘤科,江苏 苏州 215001 
王 彬 南京医科大学附属苏州市立医院肿瘤科,江苏 苏州 215001 
谭 洁 南京医科大学附属苏州市立医院肿瘤科,江苏 苏州 215001 
摘要点击次数: 672
全文下载次数: 1318
中文摘要:
      目的:探讨树突状细胞(dendritic cell,DC)共培养细胞因子诱导的杀伤细胞(cytokine-induced killer,CIK)联合化疗治疗晚期胃癌患者的近期疗效?方法:选取28例确诊为晚期胃癌并采用DC-CIK联合化疗的患者为联合治疗组,选取临床资料相近的同期进行单纯化疗的28例晚期胃癌患者为对照组,观察两组患者治疗前后外周血中T细胞亚群?细胞因子及卡氏评分(Karnofsky,KPS)的变化及临床疗效,并记录其不良反应?结果:联合治疗组患者治疗后CD3+?CD4+?CD56+和CD4+/CD8+的比例无明显变化(P > 0.05),对照组CD3+?CD4+和CD4+/CD8+的比例治疗后明显下降(P < 0.05);联合治疗组的细胞因子IL-12和IFN-γ的水平治疗后有所上升(P < 0.05),治疗组IL-2?IL-12和TNF-α的水平治疗后有所下降(P < 0.05)?联合治疗组的疾病控制率为78.6%,与对照组(53.6%)的差别有统计学意义(P < 0.05),KPS评分总提高率为82.14%,与对照组的57.14%差别有统计学意义(P < 0.05)?结论:与单纯化疗相比,DC-CIK联合化疗能提高患者的免疫功能及生活质量,DC-CIK免疫治疗联合化疗可望成为胃癌有效的过继免疫治疗方法?
英文摘要:
      Objective:To investigate clinical effects of dendritic cells(DC) co-cultured with cytokine-induced killer cells(CIK) combined with chemotherapy on patients with advanced gastric cancer. Methods:Twenty-eight patients with advanced gastric cancer who were treated with DC-CIK combined with chemotherapy,were taken as the combined treatment group. Another twenty-eight patients who were treated with chemotherapy alone during the same period were taken as controls. T lymphocyte subtypes,intra-cellular cytokines in peripheral blood of the patients and performance status(Karnofsky,KPS) were compared between the two groups. The clinical effects were analysed. The safety were observed. Results:The ratios of CD3+,CD4+,CD56+ and CD4+/CD8+ did not change obviously in the combined treatment group and decreased in the control group after treatment,which showed significant statistical differences (P < 0.05). The IL-12 and IFN-γ were increased after treatment in the combined treatment group(P < 0.05). The IL-2,IL-12 and TNF-αwere decreased in the control group after treatment(P < 0.05). The disease control rate(DCR) of the combined therapy group and the control group were 78.6% and 53.6% respectively,which showed a significant difference(P < 0.05). The effective rate of KPS were 82.14% and 57.14% respectively(P < 0.05). Conclusion:DC-CIK cells combined with chemotherapy can improve immune functions and elevate life quality of the patients in comparision to those who take chemotherapy alone. DC-CIK cells combined with chemotherapy is likely to be an effective adoptive immunotherapy for gastric cancer.
查看全文   查看/发表评论  下载PDF阅读器
关闭